CNBC
US · 3 hrs ago
AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.
Do you trust CNBC?
Sign in to rate
Discussion
?
No comments yet — be the first to start the discussion!